Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sartorius Stedim BiotechCHIX:DIMP 84 Return-on-Tangible-Asset is 9.59% as of Mar. 2026, which is 54% below its 10-year median of 20.91. GuruFocus rates CHIX:DIMP with a GF Score™ of 84/100 and a GF Value™ of €208.05 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 856 Medical Devices & Instruments companies, Sartorius Stedim Biotech ranks better than 74.07% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Sartorius Stedim Biotech's annualizedNet Income for the quarter that ended in Mar. 2026 was €352 Mil. Sartorius Stedim Biotech's average total tangible assets for the quarter that ended in Mar. 2026 was €3,675 Mil. Therefore, Sartorius Stedim Biotech's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 9.59%.
The historical rank and industry rank for Sartorius Stedim Biotech's Return-on-Tangible-Asset or its related term are showing as below:
CHIX:DIMp'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 5.1 Med: 20.91 Max: 31.87
Current: 7.26
During the past 13 years, Sartorius Stedim Biotech's highest Return-on-Tangible-Asset was 31.87%. The lowest was 5.10%. And the median was 20.91%.
CHIX:DIMp's Return-on-Tangible-Asset is ranked better than 74.07% of 856
companies
in the Medical Devices & Instruments industry
Industry Median: 0.595
vs CHIX:DIMp: 7.26
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Sartorius Stedim Biotech Return-on-Tangible-Asset Related Terms
Sartorius Stedim Biotech Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Sartorius Stedim Biotech's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:DIMP vs ISRG, BDX, MDLN: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 9.59% mean?
Sartorius Stedim Biotech (CHIX:DIMP) has a Return-on-Tangible-Asset of 9.59% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Sartorius Stedim Biotech and its competitors. This is 54% below median its historical median of 20.91. Over the past decade, Sartorius Stedim Biotech's Return-on-Tangible-Asset has ranged from 5.10 to 31.87. According to the industry distribution chart, Sartorius Stedim Biotech ranks #222 out of 856 companies in the Medical Devices & Instruments industry, placing it in the top 25.9%.
Is Sartorius Stedim Biotech's Return-on-Tangible-Asset too high?
Sartorius Stedim Biotech's current Return-on-Tangible-Asset of 9.59% is 54% below median its 10-year median of 20.91. Over the past 10 years, this metric has ranged from a low of 5.10 to a high of 31.87. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.60. Sartorius Stedim Biotech's value of 9.59% is 1511.8% above this industry median. Based on the distribution chart, Sartorius Stedim Biotech ranks #222 out of 856 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sartorius Stedim Biotech has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Return-on-Tangible-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #222 out of 856 companies for Return-on-Tangible-Asset. This puts Sartorius Stedim Biotech in the upper half of its industry. The industry median Return-on-Tangible-Asset is 0.60. Sartorius Stedim Biotech's value of 9.59% is 1511.8% above this benchmark. Historically, Sartorius Stedim Biotech's own Return-on-Tangible-Asset has ranged from 5.10 to 31.87 over the past decade. While the company's 10-year median is 20.91 vs. the industry median of 0.60, Sartorius Stedim Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.60, based on 856 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius Stedim Biotech's current Return-on-Tangible-Asset of 9.59% is 1511.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Sartorius Stedim Biotech and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius Stedim Biotech's current Return-on-Tangible-Asset is 9.59%, which is 54% below median its own 10-year median of 20.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Modestly Undervalued. The stock's GF Value™ is €208.05, compared to a current price of €179.05 — trading 13.9% below its estimated fair value. The current Return-on-Tangible-Asset is 9.59%, which is 54% below median its 10-year median of 20.91 and 1511.8% above the Medical Devices & Instruments industry median of 0.60. Sartorius Stedim Biotech's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current Return-on-Tangible-Asset is 9.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of €179.05 is trading 13.9% below its estimated GF Value™ of €208.05.
GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.
Key valuation signals for CHIX:DIMP:
Return-on-Tangible-Asset: 9.59% (54% below median its 10-year median of 20.91)
GF Value™: €208.05 vs. price of €179.05 (13.9% below fair value)
Industry Position: 1511.8% above the Medical Devices & Instruments median (#222 of 856)
No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
84GF Score
Get the complete analysis for CHIX:DIMP
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DIMP has been successfully added to your 
